AN ARTIFICIAL SEQUENCE-BASED PROTEIN RECEPTOR ARRAY

基于人工序列的蛋白质受体阵列

• 批准号: 6294308
• 负责人: Chin-Shiou Huang
• 金额: $ 10.8万
• 依托单位: ASPIRA BIOSYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294308
• 关键词: acidity /alkalinity; bioengineering /biomedical engineering; chemical structure function; crosslink; fluorescence spectrometry; fluorescent dye /probe; gene expression; high throughput technology; informatics; intermolecular interaction; intracellular transport; microarray technology; molecular shape; peptide chemical synthesis; polymers; posttranslational modifications; protein purification; protein sequence; proteomics; receptor; technology /technique development

DESCRIPTION (applicant's abstract): Our goal under this SBIR is to demonstrate the feasibility of using a novel Artificial Sequence-based Protein REceptor (ASPIRE) for the creation of a "protein chip." The development of new protein separation technology is essential to bridge the gap between genomics and rational disease diagnostics and treatment. Preliminary results indicate that we can design an artificial receptor, based solely on the predicted protein sequence, capable of purifying a target protein from a cell lysate. To prove that such a receptor will be useful for large-scale high-throughput proteome separation and analysis, we plan to 1) demonstrate that the technology is applicable to 6-10 representative proof of principle proteins; 2) optimize the critical receptor properties for efficient separation of complex samples; and 3) create an array of receptors capable of separating labeled proteins. Our data indicate that a chip based on the ASPIRE technology will be roughly 250x faster and lOx more sensitive than two-dimensional gel electrophoresis paired with mass spectrometry. In addition to the analysis of protein expression patterns, ASPIRE protein chips will allow researchers to conduct large-scale parallel analysis of posttranslational modifications and intracellular trafficking control much of cell regulation. We expect that this technology will have far-reaching implications for basic research, drug development, and disease diagnosis. PROPOSED COMMERCIAL APPLICATION: The market for proteomics is estimated at $4 billion and is rapidly growing. A protein chip enabling proteomics would allow for 1) rapid identification of molecular causes of disease and therapeutic targets 2) efficient screening of small molecules for therapeutic efficacy and toxicity, and 3) rational diagnostic and treatment strategies based on individual molecular profiling.

描述（申请人的摘要）：我们在此 SBIR 下的目标是证明 使用新型基于人工序列的蛋白质受体的可行性 （ASPIRE）创建“蛋白质芯片”。新蛋白质的开发 分离技术对于弥合基因组学和基因组学之间的差距至关重要 合理的疾病诊断和治疗。初步结果表明 我们可以仅根据预测的蛋白质设计人工受体 序列，能够从细胞裂解物中纯化靶蛋白。证明 这种受体将有助于大规模高通量蛋白质组研究 分离和分析，我们计划 1）证明该技术是 适用于6-10个代表性的原理蛋白证明； 2）优化 有效分离复杂样品的关键受体特性；和 3) 创建一系列能够分离标记蛋白质的受体。我们的 数据表明，基于 ASPIRE 技术的芯片将大约 250 倍 比配对的二维凝胶电泳更快、更灵敏 10 倍 与质谱分析。除了蛋白质表达分析 ASPIRE 蛋白质芯片将允许研究人员进行大规模 翻译后修饰和细胞内修饰的平行分析 贩运控制着大部分细胞调节。我们期望这项技术 将对基础研究、药物开发等产生深远影响 疾病诊断。 拟议的商业应用： 蛋白质组学市场估计价值 40 亿美元，并且正在快速增长。一个 实现蛋白质组学的蛋白质芯片将允许 1) 快速识别 疾病的分子原因和治疗靶点2）高效筛选 小分子的治疗功效和毒性，以及3）合理诊断 以及基于个体分子谱分析的治疗策略。